Probably Genetic

probablygenetic.com →

+16%

est. 2Y upside i

Healthcare

Patient Intelligence Platform for Genetic Disease

Rank

#222

Sector

Biotechnology, HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Medium

Probably Genetic presents a moderate upside opportunity for a job seeker, driven by its impressive >6x YoY revenue growth and current profitability.

Last updated: March 10, 2026

Bull (40%)+300%

Probably Genetic leverages its proprietary AI and growing patient data platform to significantly expand its free testing programs and pharmaceutical partnerships, capturing a larger share of the rare disease genetic testing market. Annual recurring revenue continues to grow rapidly, reaching over $100M by 2028, justifying a $280M+ valuation at a 2.5x revenue multiple, well above the current estimated $70M.

Base (35%)+100%

The company maintains its strong growth trajectory, expanding its partnerships with drug developers and patient advocacy groups while steadily increasing its insurance-billed testing. Revenue reaches approximately $60M by 2028, leading to an acquisition or next funding round at a $140M valuation, representing a 2x return on the current estimated valuation.

Bear (25%)-60%

Increased competition from larger diagnostic labs and genetic testing companies, coupled with persistent operational challenges or regulatory hurdles, slows growth significantly. Revenue stagnates, and a down round or acquisition at a distressed valuation of $28M (a 60% decrease) wipes out most common stock value due to investor liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Investors hold an estimated $11M in liquidation preferences ahead of common stock, based on the total funding of $11M and an estimated current valuation of $70M.

Dilution Risk

moderate

While the company is profitable and has low capital intensity, as a Series B company, further funding rounds are likely before an exit, which could lead to additional dilution for existing equity holders.

Secondary Liquidity

limited

Probably Genetic stock does not trade on public exchanges, and selling shares requires working directly with the company or a secondary marketplace like Nasdaq Private Market, typically with company approval.

Engineering — 3 roles

Marketing — 1 role

View all 4 open roles at Probably Genetic →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Probably Genetic's data — designed to show you've done your homework.

  • 1

    “Given the strong growth in annual recurring revenue, how is Probably Genetic planning to scale its operations and customer support to avoid potential bottlenecks or service delays, particularly in light of past reported issues with test result turnaround times?”

  • 2

    “With major players like Illumina and Quest Diagnostics in the broader genetic testing market, what specific strategies is Probably Genetic employing to strengthen its competitive moat and defend its market position in rare disease diagnostics against potential expansion by these incumbents?”

  • 3

    “Considering the Series 2 funding round and the goal of providing meaningful equity, what is the company's anticipated timeline and strategy for a liquidity event (e.g., IPO or acquisition) for employees, and how does the current preference stack impact common stock holders?”

Community

Valuation Sentiment

Our model estimates +16% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.